Abbott Laboratories (ABT) Gross Profit (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Gross Profit data on file, last reported at $6.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 6.52% year-over-year to $6.3 billion; the trailing twelve-month figure through Mar 2026 stood at $25.4 billion (up 7.45% YoY), and the FY2025 full-year result was $25.0 billion, up 7.59% from the prior year.
• Gross Profit eased to $6.3 billion in Q1 2026, from $6.5 billion in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $6.9 billion in Q1 2022 to a low of $5.4 billion in Q1 2023.
• A 5-year average of $6.0 billion and a median of $5.9 billion in 2025 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit climbed 19.86% in 2022 and slipped 21.6% in 2023, its largest moves.
• Tracing ABT's Gross Profit over 5 years: stood at $5.5 billion in 2022, then rose by 3.4% to $5.7 billion in 2023, then grew by 6.1% to $6.0 billion in 2024, then advanced by 8.37% to $6.5 billion in 2025, then slipped by 4.02% to $6.3 billion in 2026.
• Business Quant data shows ABT's Gross Profit at $6.3 billion in Q1 2026, $6.5 billion in Q4 2025, and $6.3 billion in Q3 2025.